Barclays Maintains Equal-Weight on Apellis Pharmaceuticals, Raises Price Target to $41

Barclays analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and raises the price target from $24 to $41.